Journal
BIOMOLECULES
Volume 11, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/biom11030433
Keywords
Parkinson's disease; gut microbiota; therapeutic modulation; gut-brain axis; prebiotics; probiotics; antibiotics; synbiotics; Mediterranean diet; fecal transplants; live biotherapeutic products
Categories
Funding
- La Caixa Banking Foundation [LCF/BQ/PR19/11700005]
Ask authors/readers for more resources
Research indicates that gut microbiota plays a crucial role in the development and progression of Parkinson's disease, making microbiota-based therapeutic strategies a potential treatment option. Various microbiota-based treatment strategies have been developed for Parkinson's disease, but the field faces challenges in implementation and further research.
Parkinson's disease (PD) is a multifactorial neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, and for which no disease-modifying treatments exist. Neurodegeneration and neuropathology in different brain areas are manifested as both motor and non-motor symptoms in patients. Recent interest in the gut-brain axis has led to increasing research into the gut microbiota changes in PD patients and their impact on disease pathophysiology. As evidence is piling up on the effects of gut microbiota in disease development and progression, another front of action has opened up in relation to the potential usage of microbiota-based therapeutic strategies in treating gastrointestinal alterations and possibly also motor symptoms in PD. This review provides status on the different strategies that are in the front line (i.e., antibiotics; probiotics; prebiotics; synbiotics; dietary interventions; fecal microbiota transplantation, live biotherapeutic products), and discusses the opportunities and challenges the field of microbiome research in PD is facing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available